Cramer's lightning round: Neogenomics, Yeti, Nutanix and more stocks

Key Points
  • It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Neogenomics: "Neogenomics is another one of these diagnostic companies that might have something that could work against cancer. I have yet to say no to any of those. I think that it is a good spec ... because that is the holy grail."

Yeti: "I am going to say: up 100% for the year, I am not going to push it here. I'm not."

Nutanix: "I know that Nutanix is making a little bit of a comeback, but it's too hard for me. I just think that they have to put a couple of quarters together that are good, and they have not done that."

Cadence Design Systems: "I'm going to say let's hold off. This stock is overvalued."

WATCH: Cramer's lightning round

VIDEO4:0204:02
Cramer's lightning round: Neogenomics, Yeti, Nutanix and more stocks

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com